Psilocybin
Mental health-focused atai chops 30% of staff to ‘further focus’ on looming readouts
Chopping the pipeline and dropping out of partnerships were not enough to keep atai Life Sciences’ finances in check after all.
More than half a year…
Chopping the pipeline and dropping out of partnerships were not enough to keep atai Life Sciences’ finances in check after all.
More than half a year after announcing those changes, the company has taken another long look at its pipeline of drugs for mental health disorders and laid off 30% of its staffers. The layoffs will mainly impact those in general and administration and non-clinical development roles, atai added.
A spokesperson told Endpoints News that “because the decision was geared to ensure we are equipped with the right team to hit our clinical program milestones (some accelerated) and generate meaningful data, the 30% of employees who were affected came primarily from general and administrative areas rather than clinical development.
CEO and co-founder Florian Brand called the decision part of an effort to “further focus our capital allocation towards generating meaningful clinical readouts in the near-term” and operate more efficiently.
Many biotechs have cited similar reasons in shrinking their workforce in recent months, as public and private companies alike find themselves having to go longer with less money — until they hit good enough data to entice investors.
Atai revealed in August that it’s implementing a “company-wide cost optimization” to save money, with funding discontinued for certain discovery programs. But its shares $ATAI kept going down and are now trading at $1.58.
It is now banking on several key programs, including RL-007, with which it’s recently dosed the first patient in a Phase IIb study in cognitive impairment associated with schizophrenia; and GRX-917, for which a Phase II study in anxiety disorder is planned.
Then there are the two candidates for treatment-resistant depression. PCN-101, an isomer of ketamine, recently flopped in a Phase IIa trial but atai is still considering next steps; COMP360 is a psilocybin therapy that is now in Phase III, and the company is speeding up the trial so that topline data are now expected in the summer of 2024.
The company now extends its cash on hand to fund operations into the first half of 2026.
psilocybin ketamine therapy depression anxiety investors shares funding trading fund capital atai atai life sciences-
Psychedelics1 week ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Law & Regulation6 days ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics1 week ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics1 week ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Psychedelics5 days ago
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
-
Ketamine1 week ago
DEA poised to move cannabis to Schedule III
-
Psychedelics1 week ago
Are ‘Ketamine Bros’ Ruining It for Everyone Else?
-
Psychedelics5 days ago
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials